Final Appraisal Recommendation

Brimonidine (Mirvaso®) 3 mg/g gel

Submission by Galderma (UK) Ltd

Recommendation of AWMSG

Brimonidine (Mirvaso®) is recommended for restricted use within NHS Wales for the symptomatic treatment of facial erythema of rosacea in adult patients.

Brimonidine (Mirvaso®) should be restricted for use in patients with moderate to severe persistent facial erythema associated with rosacea.

Brimonidine (Mirvaso®) is not recommended for use within NHS Wales outside of this subpopulation.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2168), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company’s response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

<table>
<thead>
<tr>
<th>Marketing authorisation holder on first issue</th>
<th>Galderma (UK) Ltd</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of first issue</td>
<td>July 2015</td>
</tr>
<tr>
<td>Last reviewed</td>
<td>March 2019</td>
</tr>
</tbody>
</table>

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:


NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendations. Accreditation is valid for 5 years from October 2016. More information on accreditation can be viewed at http://www.nice.org.uk/about/what-we-do/accreditation